Is prospective MRI mapping of the changes in the volume of the prostate gland in prostate cancer patients undergoing 6 months of neo-adjuvant androgen deprivation therapy a step towards a trial to determine those who may benefit from treatment intensification or extended duration?
David Robert Harry ChristieChristopher F SharpleyNatalia MitinaEamonn MacAteerJames E JacksonDominic LunnPublished in: Journal of medical imaging and radiation oncology (2020)
Reductions in volume continue throughout a 6-month course of neo-adjuvant therapy but are greatest during the first 6 weeks. Although individualisation of the duration or intensity of the hormone treatment warrants further investigation, the role of prostate gland volume reduction remains uncertain. More detailed studies of tumour volume might be possible if the imaging required was acceptable and accessible to patients.
Keyphrases
- prostate cancer
- patients undergoing
- high resolution
- radical prostatectomy
- end stage renal disease
- newly diagnosed
- early stage
- ejection fraction
- prognostic factors
- benign prostatic hyperplasia
- randomized controlled trial
- stem cells
- study protocol
- combination therapy
- peritoneal dialysis
- photodynamic therapy
- bone marrow
- contrast enhanced
- mesenchymal stem cells
- phase iii
- replacement therapy
- gestational age
- patient reported
- preterm birth
- diffusion weighted imaging